Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

183 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Tepotinib in Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations.
Paik PK, Felip E, Veillon R, Sakai H, Cortot AB, Garassino MC, Mazieres J, Viteri S, Senellart H, Van Meerbeeck J, Raskin J, Reinmuth N, Conte P, Kowalski D, Cho BC, Patel JD, Horn L, Griesinger F, Han JY, Kim YC, Chang GC, Tsai CL, Yang JC, Chen YM, Smit EF, van der Wekken AJ, Kato T, Juraeva D, Stroh C, Bruns R, Straub J, Johne A, Scheele J, Heymach JV, Le X. Paik PK, et al. Among authors: stroh c. N Engl J Med. 2020 Sep 3;383(10):931-943. doi: 10.1056/NEJMoa2004407. Epub 2020 May 29. N Engl J Med. 2020. PMID: 32469185 Free PMC article. Clinical Trial.
Landscape and Clonal Dominance of Co-occurring Genomic Alterations in Non-Small-Cell Lung Cancer Harboring MET Exon 14 Skipping.
Le X, Hong L, Hensel C, Chen R, Kemp H, Coleman N, Ciunci CA, Liu SV, Negrao MV, Yen J, Xia X, Scheuenpflug J, Stroh C, Juraeva D, Tsao A, Hong D, Raymond V, Paik P, Zhang J, Heymach JV. Le X, et al. Among authors: stroh c. JCO Precis Oncol. 2021 Dec 13;5:PO.21.00135. doi: 10.1200/PO.21.00135. eCollection 2021. JCO Precis Oncol. 2021. PMID: 34957368 Free PMC article.
Real-world insights into patients with advanced NSCLC and MET alterations.
Bittoni M, Yang JC, Shih JY, Peled N, Smit EF, Camidge DR, Arasada RR, Oksen D, Boutmy E, Stroh C, Johne A, Carbone DP, Paik PK. Bittoni M, et al. Among authors: stroh c. Lung Cancer. 2021 Sep;159:96-106. doi: 10.1016/j.lungcan.2021.06.015. Epub 2021 Jul 16. Lung Cancer. 2021. PMID: 34320421 Free PMC article.
Translational pharmacokinetic-pharmacodynamic modeling of preclinical and clinical data of the oral MET inhibitor tepotinib to determine the recommended phase II dose.
Xiong W, Friese-Hamim M, Johne A, Stroh C, Klevesath M, Falchook GS, Hong DS, Girard P, El Bawab S. Xiong W, et al. Among authors: stroh c. CPT Pharmacometrics Syst Pharmacol. 2021 May;10(5):428-440. doi: 10.1002/psp4.12602. Epub 2021 May 1. CPT Pharmacometrics Syst Pharmacol. 2021. PMID: 33818908 Free PMC article.
Brain penetration and efficacy of tepotinib in orthotopic patient-derived xenograft models of MET-driven non-small cell lung cancer brain metastases.
Friese-Hamim M, Clark A, Perrin D, Crowley L, Reusch C, Bogatyrova O, Zhang H, Crandall T, Lin J, Ma J, Bachner D, Schmidt J, Schaefer M, Stroh C. Friese-Hamim M, et al. Among authors: stroh c. Lung Cancer. 2022 Jan;163:77-86. doi: 10.1016/j.lungcan.2021.11.020. Epub 2021 Dec 11. Lung Cancer. 2022. PMID: 34942492 Free article.
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
Van Cutsem E, Köhne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, D'Haens G, Pintér T, Lim R, Bodoky G, Roh JK, Folprecht G, Ruff P, Stroh C, Tejpar S, Schlichting M, Nippgen J, Rougier P. Van Cutsem E, et al. Among authors: stroh c. N Engl J Med. 2009 Apr 2;360(14):1408-17. doi: 10.1056/NEJMoa0805019. N Engl J Med. 2009. PMID: 19339720 Free article. Clinical Trial.
SHP2 Inhibition Influences Therapeutic Response to Tepotinib in Tumors with MET Alterations.
Pudelko L, Jaehrling F, Reusch C, Vitri S, Stroh C, Linde N, Sanderson MP, Musch D, Lebrun CJ, Keil M, Esdar C, Blaukat A, Rosell R, Schumacher KM, Karachaliou N. Pudelko L, et al. Among authors: stroh c. iScience. 2020 Nov 20;23(12):101832. doi: 10.1016/j.isci.2020.101832. eCollection 2020 Dec 18. iScience. 2020. PMID: 33305187 Free PMC article.
Targeting the MET Receptor Tyrosine Kinase as a Strategy for Radiosensitization in Locoregionally Advanced Head and Neck Squamous Cell Carcinoma.
Nisa L, Francica P, Giger R, Medo M, Elicin O, Friese-Hamim M, Wilm C, Stroh C, Bojaxhiu B, Quintin A, Caversaccio MD, Dettmer MS, Buchwalder M, Brodie TM, Aebersold DM, Zimmer Y, Carey TE, Medová M. Nisa L, et al. Among authors: stroh c. Mol Cancer Ther. 2020 Feb;19(2):614-626. doi: 10.1158/1535-7163.MCT-18-1274. Epub 2019 Nov 19. Mol Cancer Ther. 2020. PMID: 31744898
Molecular biomarkers in non-small-cell lung cancer: a retrospective analysis of data from the phase 3 FLEX study.
O'Byrne KJ, Gatzemeier U, Bondarenko I, Barrios C, Eschbach C, Martens UM, Hotko Y, Kortsik C, Paz-Ares L, Pereira JR, von Pawel J, Ramlau R, Roh JK, Yu CT, Stroh C, Celik I, Schueler A, Pirker R. O'Byrne KJ, et al. Among authors: stroh c. Lancet Oncol. 2011 Aug;12(8):795-805. doi: 10.1016/S1470-2045(11)70189-9. Epub 2011 Jul 22. Lancet Oncol. 2011. PMID: 21782507
183 results